ClinicalTrials.gg
CompletedNCT00831922Updated Dec 11, 2018

Efficacy of Oral AB1010 in Adult Patients With Active Rheumatoid Arthritis

A Phase 2 interventional study of masitinib (AB1010) and masitinib (AB1010) in Rheumatoid Arthritis, sponsored by AB Science. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-12-11.

Sponsored by AB Science · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
43
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The objective of this study is to evaluate the activity of 2 oral doses of AB1010 in subjects suffering from active RA who have shown an inadequate response to one DMARD including MTX or anti-TNF, after 3 months (12 weeks) of treatment.

The safety and efficacy will be evaluated on:

Rate of patients achieving ACR 20, 50, 70 and 90 DAS (disease activity score) after 3 months treatment ACRn after 3 months treatment Therapeutic maintenance of AB1010 at 3 months Quality of Life assessed by SF12 Health Assessment Questionnaire (HAQ) Clinical and biological safety Pharmacokinetic profile of AB1010

02

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Rheumatoid Arthritis
  • DMARD failure
  • ACR
03

In context

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

This study's enrollment of 43 is below the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.

Browse Arthritis, Rheumatoid studies →

Lead sponsor

AB Science is the lead sponsor of 39 studies on the registry; 5 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Meet American College of Rheumatology (ACR) criteria for RA
  2. Have active RA
  3. ACR functional class I-III
  4. Disease onset at > 16 years of age
  5. Disease duration of at least 6 months
  6. Failure to one DMARD including methotrexate and anti-TNF alpha

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or breastfeeding women
  2. Inadequate bone marrow function
  3. Current use of a DMARD within 4 weeks (or 5 half-lives, whichever is longer) of screening except for leflunomide which requires a specific wash-out
  4. Any previous use of recombinant IL1-Ra
  5. Current use of more than 1 non steroidal anti-inflammatory drug (NSAID) or change of dose of the NSAID within 4 weeks of baseline or NSAID use greater than the maximum recommended dose
  6. Within 4 weeks before baseline, use of more than 10 mg/day of prednisone or equivalent or change in the dose of prednisone or equivalent, or having intra-articular injection or bolus intramuscular or intravenous treatment with corticosteroids (>20 mg prednisone or equivalent
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
43 participants (actual)

Study arms

  • Experimental
    1

    masitinib (AB1010) 3 mg/kg/day

    Drug: masitinib (AB1010)

  • Experimental
    2

    masitinib (AB1010) 6 mg/kg/day

    Drug: masitinib (AB1010)

Interventions

06

What researchers measure

Primary outcomes

  1. rate of patients achieving ACR 20, 50, 70 and 90 at 12 weeks

    Time frame: 12 weeks

Secondary outcomes

  1. DAS (disease activity score) at 12 weeks

    Time frame: 12 weeks

  2. ACRn at 12 weeks

    Time frame: 12 weeks

  3. improvement of quality of life assessed by SF12 at 12 weeks

    Time frame: 12 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Tebib J, Mariette X, Bourgeois P, Flipo RM, Gaudin P, Le Loet X, Gineste P, Guy L, Mansfield CD, Moussy A, Dubreuil P, Hermine O, Sibilia J. Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study. Arthritis Res Ther. 2009;11(3):R95. doi: 10.1186/ar2740. Epub 2009 Jun 23. PubMed 19549290 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2004 and a primary completion of Oct 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2009
First posted
Jan 29, 2009
Start
Sep 2004
Primary completionActual
Oct 2006
Last update
Dec 11, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00831922
Lead sponsor
AB Science
Responsible party
Sponsor
First posted
Jan 29, 2009
Start date
Sep 2004
Primary completion
Oct 2006
Last update
Dec 11, 2018

Study contacts

Xavier Mariette, MD, PhD
principal investigator · Hôpital Kremlin Bicêtre, France

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Masitinib

Start the discussion